Back to results
US 2024/0417423 A1Published application
Deuterated positive nmda-modulating compounds and methods of use thereof
AssigneeSage Therapeutics, Inc.
InventorMaria-Jesus Blanco-Pillado
Life of this patent
Estimating the term…
Abstract
Deuterated compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. These compounds are contemplated as useful for the prevention and treatment of a variety of CNS-related conditions.
Claims38
A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof;
- wherein:
- each of R3, R18, R19, R20a and R24a is independently C1-3alkyl optionally substituted with 1 or more independent occurrences of deuterium;
- each of R1a, R1b, R2a, R2b, R4a, R4b, R5, R6a, R6b, R7a, R7b, R8, R9, R11a, R11b, R12a, R12b, R14, R15a, R15b, R16a, R16b, R17, R20b, R21a, R21b, R23a, and, R23b is independently selected from a group consisting of hydrogen and deuterium;
- provided that at least one of R3, R18, R19, R20a and R24a is substituted with 1 or more independent occurrences of deuterium, or at least one of R1a, R1b, R2a, R2b, R4a, R4b, R5, R6a, R6b, R7a, R7b, R8, R9, R11a, R11b, R12a, R12b, R14, R15a, R15b, R16a, R16b, R17, R20b, R21a, R21b, R23a, and R23b is deuterium;
- represents a single or double bond;
- provided if the bond between C5 and C6 is a single bond, then R5 is in the alpha configuration.
4 more elements
Dependencies are inferred from the claim text.